Literature DB >> 25561688

Opportunities for improvement in anti-thrombotic therapy and other strategies for the management of acute coronary syndromes: Insights from EPICOR, an international study of current practice patterns.

Héctor Bueno1, Peter Sinnaeve2, Lieven Annemans3, Nicolas Danchin4, Muriel Licour5, Jesús Medina6, Stuart Pocock7, Joaquín Sánchez-Covisa6, Robert F Storey8, J Wouter Jukema9, Uwe Zeymer10, Frans Van de Werf2.   

Abstract

AIMS: To describe international patterns and opportunities for improvement of pre- and in-hospital care of patients hospitalized for acute coronary syndromes (ACS), with special focus on anti-thrombotic therapy. METHODS AND
RESULTS: EPICOR (long-tErm follow-uP of anti-thrombotic management patterns In acute CORonary syndrome patients), an international, cohort study, which enrolled 10,568 consecutive ACS survivors from 555 hospitals in 20 countries across Europe and Latin America (September 2010 to March 2011), prospectively registered detailed information on pre- and in-hospital management. Globally, 4738 (44.8%) were attended before hospitalization, 4241 (40.1%) had an ECG, 2119 (20%) received anti-platelet therapy and 101 STEMI patients (2%) fibrinolysis. In-hospital, 7944 patients (75.2%) received dual anti-platelet therapy, most often with clopidogrel (69.7%), and less with prasugrel (5.4%); 1705 (16.1%) had triple anti-platelet therapy, and 849 (8%) single anti-platelet therapy. STEMI patients more often received pre-hospital anti-thrombotics, and prasugrel, GP IIb/IIIa inhibitors and UFH in-hospital (all p < 0.001). More NSTE-ACS patients received clopidogrel, single anti-platelet therapy, and fondaparinux (all p < 0.001). As many as 33% of ACS patients were medically managed. A significant decreasing gradient was found between Northern, Southern and Eastern Europe and Latin America in use of more potent patterns of anti-platelet therapy, reperfusion therapy and invasive strategy.
CONCLUSION: This large international study shows room for improvement in use of anti-thrombotic drugs and other strategies for optimal management of ACS, including pre-hospital ECG and anti-thrombotic therapy. Regional practice differences not based on evidence or conditioned by economic constraints should be reduced. © The European Society of Cardiology 2015.

Entities:  

Keywords:  Acute coronary syndromes; anti-coagulants; anti-platelet drugs; real-world

Mesh:

Substances:

Year:  2015        PMID: 25561688     DOI: 10.1177/2048872614565912

Source DB:  PubMed          Journal:  Eur Heart J Acute Cardiovasc Care        ISSN: 2048-8726


  9 in total

Review 1.  Switching P2Y12-receptor inhibitors in patients with coronary artery disease.

Authors:  Fabiana Rollini; Francesco Franchi; Dominick J Angiolillo
Journal:  Nat Rev Cardiol       Date:  2015-08-18       Impact factor: 32.419

Review 2.  Potential Usefulness of Clopidogrel Pharmacogenetics in Cerebral Endovascular Procedures and Carotid Artery Stenting.

Authors:  Jorge Duconge; Dagmar F Hernandez-Suarez
Journal:  Curr Clin Pharmacol       Date:  2017

3.  Regional variations in hospital management and post-discharge mortality in patients with non-ST-segment elevation acute coronary syndrome.

Authors:  Héctor Bueno; Xavier Rossello; Stuart Pocock; Frans Van de Werf; Chee Tang Chin; Nicolas Danchin; Stephen W-L Lee; Jesús Medina; Ana Vega; Yong Huo
Journal:  Clin Res Cardiol       Date:  2018-04-16       Impact factor: 5.460

4.  Prevalence of pharmacogenomic variants affecting the efficacy of clopidogrel therapy in the Hispanic Community Health Study/Study of Latinos cohort.

Authors:  Kyle Melin; Jee-Young Moon; Qibin Qi; Dagmar F Hernandez-Suarez; Jorge Duconge; Simin Hua; Sara Gonzalez; Donglin Zeng; Robert C Kaplan
Journal:  Pharmacogenomics       Date:  2018-12-06       Impact factor: 2.533

Review 5.  Antithrombotic therapy for patients with STEMI undergoing primary PCI.

Authors:  Francesco Franchi; Fabiana Rollini; Dominick J Angiolillo
Journal:  Nat Rev Cardiol       Date:  2017-02-23       Impact factor: 32.419

6.  Number of Antithrombotic Drugs Used Early and In-hospital Outcomes in Acute Coronary Syndromes.

Authors:  Roberto Martín-Asenjo; John Gregson; Xavier Rossello; Frans Van de Werf; Jesús Medina; Nicolas Danchin; Stuart Pocock; Héctor Bueno
Journal:  J Cardiovasc Transl Res       Date:  2021-01-08       Impact factor: 4.132

7.  Impact of Diabetes Mellitus and Chronic Kidney Disease on Cardiovascular Outcomes and Platelet P2Y12 Receptor Antagonist Effects in Patients With Acute Coronary Syndromes: Insights From the PLATO Trial.

Authors:  Francesco Franchi; Stefan K James; Tatevik Ghukasyan Lakic; Andrzej J Budaj; Jan H Cornel; Hugo A Katus; Matyas Keltai; Frederic Kontny; Basil S Lewis; Robert F Storey; Anders Himmelmann; Lars Wallentin; Dominick J Angiolillo
Journal:  J Am Heart Assoc       Date:  2019-03-19       Impact factor: 5.501

8.  Prehospital and in-hospital use of healthcare resources in patients surviving acute coronary syndromes: an analysis of the EPICOR registry.

Authors:  Lieven Annemans; Nicolas Danchin; Frans Van de Werf; Stuart Pocock; Muriel Licour; Jesús Medina; Héctor Bueno
Journal:  Open Heart       Date:  2016-02-24

9.  International patterns of dual antiplatelet therapy duration after acute coronary syndromes.

Authors:  Héctor Bueno; Stuart Pocock; Nicolas Danchin; Lieven Annemans; John Gregson; Jesús Medina; Frans Van de Werf
Journal:  Heart       Date:  2016-08-08       Impact factor: 5.994

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.